Sino Biopharma launches SBP Group global brand to drive international expansion

• Sino Biopharmaceutical launched global brand SBP Group, positioning the business for international expansion in 2026.
• Strategy targets product globalization via in-house R&D, acquisitions, global partnerships, direct commercial expansion in key overseas markets.
• Plan includes continued investment in global talent, organizational capabilities, infrastructure to support overseas growth.
• Completed four out-licensing deals with multinational drugmakers, exceeding USD 1 billion upfront, with potential value above USD 7 billion.
• 2026 deals include Sanofi rovadicitinib license up to USD 1.53 billion; AstraZeneca TQC3721 license up to USD 1.9 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via CNW (Ref. ID: 202608190727CANADANWCANADAPR_C3270) on August 19, 2026, and is solely responsible for the information contained therein.